IVCRQ · Invacare Holdings Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $165.48M | - | $170.41M | $189.02M | $200.99M | - | $224.20M | $225.86M | - | $211.91M |
| Cost of Revenue | $121.64M | - | $139.03M | $141.03M | $153.26M | - | $163.89M | $165.05M | - | $151.87M |
| Gross Profit | $43.84M | - | $31.38M | $47.98M | $47.73M | - | $60.31M | $60.82M | - | $60.04M |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $53.81M | - | $55.37M | $58.62M | $60.56M | - | $56.13M | $63.77M | - | $55.53M |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $3.57M | - | - | - | $3.94M | - | - | $4.08M | - | - |
| Operating Income | ($10.45M) | - | ($33.44M) | ($14.79M) | ($16.63M) | - | ($24.77M) | ($3.49M) | - | $2.93M |
| Interest Expense | $9.10M | - | $7.35M | $6.23M | $6.25M | - | $6.28M | $6.08M | - | $7.40M |
| Income Tax | $940.0K | - | $920.0K | $920.0K | $1.32M | - | $1.84M | $1.12M | - | $2.05M |
| Net Income | ($41.18M) | - | ($34.35M) | ($21.94M) | ($24.20M) | - | ($22.76M) | ($10.70M) | - | ($7.28M) |
| EPS - Basic | ($1.08) | - | ($0.92) | ($0.62) | ($0.69) | - | ($0.65) | ($0.31) | - | ($0.21) |
| EPS - Diluted | ($1.08) | - | ($0.92) | ($0.62) | ($0.69) | - | ($0.65) | ($0.31) | - | ($0.21) |
Balance Sheet
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $66.28M | $58.79M | $45.44M | $43.91M | $52.34M | $83.75M | $73.66M | $78.25M | $105.30M | $86.83M |
| Accounts Receivable | $82.66M | $87.95M | $80.11M | $90.95M | $106.38M | $117.11M | $115.92M | $120.71M | $108.59M | $108.96M |
| Inventory | $103.64M | $112.56M | $120.69M | $138.81M | $147.35M | $144.27M | $151.34M | $144.54M | $115.48M | $145.45M |
| Accounts Payable | $72.59M | $104.59M | $95.97M | $111.56M | $121.11M | $130.04M | $110.23M | $110.37M | $85.42M | $93.16M |
| Current Assets | $285.79M | $299.32M | $294.82M | $317.05M | $350.48M | $385.39M | $377.36M | $383.68M | $374.47M | $379.13M |
| Total Assets | $762.12M | $770.97M | $757.61M | $812.62M | $867.27M | $909.53M | $922.08M | $973.85M | $945.98M | $943.85M |
| Current Liabilities | $195.90M | $220.13M | $222.68M | $227.61M | $233.20M | $247.25M | $230.44M | $244.89M | $230.39M | $233.28M |
| Long-term Debt | $137.24M | $354.09M | $333.13M | $311.49M | $309.05M | $305.02M | $306.33M | $299.47M | $239.44M | $238.20M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | $45.94M | $81.09M | $81.05M | $147.60M | $189.31M | $218.49M | $239.71M | $280.89M | $333.85M | $330.49M |
| Retained Earnings | ($119.60M) | ($78.43M) | ($57.85M) | ($23.50M) | ($1.55M) | $22.64M | $20.71M | $43.47M | $58.54M | $63.66M |
Cash Flow
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($30.61M) | - | - | - | ($27.70M) | - | - | ($13.76M) | - | - |
| Investing Cash Flow | $9.08M | - | - | - | ($2.21M) | - | - | ($4.09M) | - | - |
| Financing Cash Flow | $28.61M | - | - | - | ($1.18M) | - | - | ($2.47M) | - | - |
| CapEx | $1.98M | - | - | - | $2.13M | - | - | $4.12M | - | - |
| Free Cash Flow | ($32.59M) | - | - | - | ($29.83M) | - | - | ($17.88M) | - | - |
Ratios
| Metric | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 26.5% | - | 18.4% | 25.4% | 23.7% | - | 26.9% | 26.9% | - | 28.3% |
| Operating margin | -6.3% | - | -19.6% | -7.8% | -8.3% | - | -11.0% | -1.5% | - | 1.4% |
| EBITDA margin | -4.2% | - | - | - | -6.3% | - | - | 0.3% | - | - |
| Net margin | -24.9% | - | -20.2% | -11.6% | -12.0% | - | -10.2% | -4.7% | - | -3.4% |
| Free cash flow margin | -19.7% | - | - | - | -14.8% | - | - | -7.9% | - | - |
| FCF / Net income | 0.79 | - | - | - | 1.23 | - | - | 1.67 | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 32.5% | - | 32.5% | 31.0% | 30.1% | - | 25.0% | 28.2% | - | 26.2% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -5.4% | - | -4.5% | -2.7% | -2.8% | - | -2.5% | -1.1% | - | -0.8% |
| Return on equity | -89.6% | - | -42.4% | -14.9% | -12.8% | - | -9.5% | -3.8% | - | -2.2% |
| Return on invested capital | -4.5% | - | -6.4% | -2.5% | -2.6% | - | -3.6% | -0.5% | - | 0.4% |
| Liquidity | ||||||||||
| Current ratio | 1.46 | 1.36 | 1.32 | 1.39 | 1.50 | 1.56 | 1.64 | 1.57 | 1.63 | 1.63 |
| Quick ratio | 0.93 | 0.85 | 0.78 | 0.78 | 0.87 | 0.98 | 0.98 | 0.98 | 1.12 | 1.00 |
| Cash ratio | 0.34 | 0.27 | 0.20 | 0.19 | 0.22 | 0.34 | 0.32 | 0.32 | 0.46 | 0.37 |
| Leverage | ||||||||||
| Debt / Equity | 2.99 | 4.37 | 4.11 | 2.11 | 1.63 | 1.40 | 1.28 | 1.07 | 0.72 | 0.72 |
| Debt / Assets | 0.18 | 0.46 | 0.44 | 0.38 | 0.36 | 0.34 | 0.33 | 0.31 | 0.25 | 0.25 |
| Debt / EBITDA | - | - | - | - | - | - | - | 511.92 | - | - |
| Interest coverage | -1.1x | - | -4.5x | -2.4x | -2.7x | - | -3.9x | -0.6x | - | 0.4x |
| Equity multiplier | 16.59 | 9.51 | 9.35 | 5.51 | 4.58 | 4.16 | 3.85 | 3.47 | 2.83 | 2.86 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.22 | - | 0.22 | 0.23 | 0.23 | - | 0.24 | 0.23 | - | 0.22 |
| Inventory turnover | 1.17 | - | 1.15 | 1.02 | 1.04 | - | 1.08 | 1.14 | - | 1.04 |
| Days sales outstanding | 182d | - | 172d | 176d | 193d | - | 189d | 195d | - | 188d |
| Days inventory outstanding | 311d | - | 317d | 359d | 351d | - | 337d | 320d | - | 350d |
| Days payable outstanding | 218d | - | 252d | 289d | 288d | - | 246d | 244d | - | 224d |
| Cash conversion cycle | 275d | - | 236d | 246d | 256d | - | 280d | 271d | - | 313d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -17.7% | - | -24.0% | - | -11.0% | - | 5.8% | 3.4% | - | -10.1% |
| Revenue CAGR (3y) | -8.8% | - | -10.3% | -7.1% | -3.5% | - | -2.9% | -1.6% | - | -5.5% |
| Revenue CAGR (5y) | -6.9% | - | -7.4% | -4.1% | -2.8% | - | -3.5% | -2.6% | - | -5.7% |
| Gross profit growth (YoY) | -8.1% | - | -48.0% | - | -21.5% | - | 0.4% | -3.4% | - | -11.2% |
| Operating income growth (YoY) | 37.2% | - | -35.0% | - | -375.8% | - | - | - | - | 21.2% |
| Net income growth (YoY) | -70.2% | - | -50.9% | - | -126.2% | - | -212.8% | - | - | 9.5% |
| EPS growth (YoY) | -56.5% | - | -41.5% | - | -122.6% | - | -209.5% | - | - | 12.5% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -9.3% | - | - | - | -66.8% | - | - | -49.5% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -75.7% | -62.9% | -66.2% | - | -32.6% | -34.6% | -27.5% | -7.8% | 8.2% | 4.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Business segments
$872.46M totalEurope EMEA$499.12M · 57.2%
North America NA$340.98M · 39.1%
All Other$32.36M · 3.7%
Product / service
$998.24M totalProduct$486.19M · 48.7%
Lifestyle Products$248.32M · 24.9%
Mobility And Seating$214.40M · 21.5%
Respiratory Therapy$19.35M · 1.9%
Other Products And Services$17.05M · 1.7%
Service$12.93M · 1.3%
Peer comparison
Same SIC group: Orthopedic, Prosthetic & Surgical Appliances & Supplies
Comparing INVACARE HOLDINGS Corp against the 5 most active filers in the same SIC group.